<DOC>
	<DOC>NCT00818259</DOC>
	<brief_summary>This study will determine the appropriate dosing regimen of aprepitant and fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in pediatric participants from 0 months to 17 years of age.</brief_summary>
	<brief_title>A Study of MK-0869 (Aprepitant) and MK-0517 (Fosaprepitant) in Pediatric Participants Receiving Chemotherapy (MK-0869-134)</brief_title>
	<detailed_description>Fosaprepitant is a prodrug for aprepitant and is rapidly converted to aprepitant after intravenous administration; the pharmacological effect of fosaprepitant is attributed to aprepitant. The birth to one year old cohort will be initiated in Parts III and IV upon completion of Part II (Steps A and B) in participants &lt;6 months of age.</detailed_description>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Aprepitant</mesh_term>
	<mesh_term>Fosaprepitant</mesh_term>
	<mesh_term>Ondansetron</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Is 0 (at least 37 weeks gestation) to 17 years of age Is scheduled to receive moderately to highly nauseainducing chemotherapy or participant did not tolerate a previous chemotherapy regimen that is planned to be repeated Is expected to receive ondansetron Female participants who have begun menstruating must have a negative pregnancy test Weighs ≥3.0 kg if &lt;6 months of age, ≥6.0 kg if &gt;6 months of age, and ≥7.5 kg if &gt; 2 years of age Has a preexisting venous catheter Uses any illicit drugs or abuses alcohol Is pregnant or breast feeding Has a symptomatic central nervous system (CNS) tumor Has an infection or other uncontrolled disease other than cancer Has known history of heart QT wave prolongation</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>